Bernardo, Judith R.

HRN: 22-55-78  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/02/2023
CEFTRIAXONE 1G (VIAL)
02/02/2023
02/08/2023
IV
2gm
OD
Perianal Abscess
Waiting Final Action 
02/02/2023
CLINDAMYCIN 150MG (CAP)
02/02/2023
02/08/2023
IV
600mg
Q8h
Perianal Abscess
Waiting Final Action 
02/02/2023
METRONIDAZOLE 125MG/5ML, 60ML (BOT)
02/02/2023
02/08/2023
IV
500mg
Q8h
Perianal Abscess
Waiting Final Action 
02/02/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
02/02/2023
02/08/2023
IV
600mg
Q8
Perianal Abscess
Waiting Final Action 
02/02/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
02/02/2023
02/08/2023
IV
500mg
Q8
Perianal Abscess
Waiting Final Action 
02/06/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
02/06/2023
02/20/2023
IV
4.5
Q6h
Perianal Abscess
Waiting Final Action 
02/12/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
02/12/2023
02/19/2023
IV
500mg
Q8
Perianal Abscess
Waiting Final Action 
02/13/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
02/13/2023
02/20/2023
IV
4.5G
Q6h
Extensive Abscess
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: